New menopause drug without hormones approved by FDA. A doctor shares what to know.

The U.S. Food and Drug Administration has approved Lynkuet, a new medication that does not contain hormones to treat hot ...

Senators Propose Sweeping Changes to Generic Drug Oversight

Citing a ProPublica investigation, lawmakers are calling on the FDA to conduct more drug testing and to alert hospitals and ...

Trump's agenda for Asia trip. And, government shutdown threatens food benefits

President Trump is expected to meet with China's President Xi Jinping and discuss a trade deal. And, the government shutdown ...

US FDA approves Bayer's menopause relief drug

The U.S. Food and Drug Administration has approved Bayer's drug to ease hot flashes in menopausal women, the German company ...

Eli Lilly reports promising data for alopecia and eczema drugs, eyes label expansion

Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

Here’s What Happened When ProPublica Reporters Tried to Find Out Where a Popular Prescription Drug Was Made

We wanted to know where a widely used prescription drug that treats high cholesterol was manufactured and whether the factory ...

One in Four Adults May Use Glp-1 Drugs This Year, Upending the Food Industry

At this month’s Food and Nutrition Conference and Expo in Nashville, one buzzword dominated conversations – GLP-1 medications ...

Major cholesterol drug recalled over ‘failed dissolution’: What patients must know

Your prescription may be involved. The FDA explains why suddenly stopping your medication is more harmful than taking it.
ABC11

New menopause drug to target hot flashes without hormones gets FDA approval

The drug, elinzanetant, is expected to be available in the United States beginning in November under the brand name Lynkuet, ...

FDA unveils drugs to receive expedited review in support of 'national priorities'

The Food and Drug Administration is announcing the first round of drugs that will receive drastically expedited reviews at ...
The Manila Times

Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall Survival ...